BNTX BioNTech SE
Price Chart
Executive Summary
BioNTech filed a 6-K announcing its upcoming presentations at the 2026 ASCO Annual Meeting, including new clinical data for pumitamig (Phase 2 ROSETTA Lung-02 in 1L NSCLC) and gotistobart (Phase 2 PRESERVE-004 in platinum-resistant ovarian cancer), plus four trial-in-progress posters across its ADC and immunotherapy pipeline. The filing is a routine pipeline update with no new financial data, guidance, or regulatory milestones — the clinical data disclosed is interim and descriptive, not definitive.
Actionable Insight
Monitor ASCO presentations (May 30–June 1) for specific response rate, PFS, and OS data from the pumitamig and gotistobart abstracts — the interim data described is encouraging but lacks quantitative endpoints. The Phase 3 part of ROSETTA Lung-02 (pumitamig vs pembrolizumab) is the key catalyst to watch.
Key Facts
- BioNTech will present at ASCO 2026 (May 29–June 2) with two oral presentations and four poster presentations
- Pumitamig (PD-L1/VEGF-A bispecific) Phase 2 data in 1L NSCLC shows 'encouraging anti-tumor activity' — third global dataset with consistent signal
- Gotistobart (CTLA-4) Phase 2 data in platinum-resistant ovarian cancer shows 'durable anti-tumor activity and clinically meaningful overall survival'
- Company has 25+ Phase 2/3 trials including 13 ongoing pivotal trials and novel-novel combination trials including ADCs
- No financial figures, guidance, or regulatory submission timelines were disclosed in the filing
Financial Impact
No financial data provided; pipeline update only
Risk Factors
- Interim Phase 2 data may not replicate in larger Phase 3 trials
- No regulatory filing or approval timeline provided — pipeline remains early-stage for these assets
- Competitive landscape in 1L NSCLC (pembrolizumab standard of care) and platinum-resistant ovarian cancer (limited approved options) creates high bar for differentiation
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001776985-26-000037 |
| Document: form6-kascocurtainraiser22.htm | 0001776985-26-000037 |
| Document: 0001776985-26-000037-index-headers.html | 0001776985-26-000037 |
| Document: 0001776985-26-000037-index.html | 0001776985-26-000037 |
| Document: 0001776985-26-000037.txt | 0001776985-26-000037 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
1d ago
|
6-K
| $88.08 awaiting T+5 | awaiting T+5 | — | $85.50 (−2.93%) |
|
Jun 1, 2026
8d ago
|
6-K
| $91.70 $88.08 | ▼ −3.95% | ▼ −1.20% | $85.50 (−6.76%) |
|
May 30, 2026
10d ago
|
Press Release
| $91.70 $88.08 | ▼ −3.95% | ▼ −1.20% | $85.50 (−6.76%) |
|
May 22, 2026
18d ago
|
6-K
| $92.14 $91.70 | ▼ −0.48% | ▼ −2.15% | $85.50 (−7.21%) |
|
May 22, 2026
18d ago
|
Press Release
| $92.14 $91.70 | ▼ −0.48% | ▼ −2.14% | $85.50 (−7.21%) |
|
May 15, 2026
25d ago
|
6-K
| $88.85 $92.25 | ▲ +3.83% | ▲ +2.21% | $85.50 (−3.77%) |
|
May 7, 2026
4w ago
|
6-K
| $93.02 $92.23 | ▼ −0.85% | ▼ −2.35% | $85.50 (−8.08%) |
|
May 5, 2026
5w ago
|
6-K
| $95.50 $93.66 | ▲ +1.93% | ▲ +3.91% | $85.50 (+10.47%) |
|
May 5, 2026
5w ago
|
6-K
| $95.50 $93.66 | ▼ −1.93% | ▼ −3.91% | $85.50 (−10.47%) |
|
May 5, 2026
5w ago
|
Press Release
| $95.50 $93.34 | ▼ −2.26% | ▼ −4.25% | $85.50 (−10.47%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access